Lund, Sweden – 23 March 2015

Redoxis granted EUREKA status and € 0,6 millions in research funding together with Image Analysis Ltd (UK)

Redoxis has been granted support from the Eurostars program for the project IMAID- "Advanced In Vivo imaging for preclinical models to improve new therapies in Autoimmune Diseases".
Redoxis AB and the UK based company Image Analysis Ltd. have received Eurostars funding, of total € 0,6 millions, to help addressing unmet needs in the field of preclinical services of autoimmune diseases. Redoxis will be coordinating this Eurostars project that will start in April 2015 and continue for 2 years.

The project is expected to provide cost-effective imaging service to the pharmaceutical industry for evaluation of drugs in preclinical models autoimmune conditions. The consortium consists of Redoxis AB, specialists in immunology, animal models and target validation with the core competencies for *In Vivo* models of autoimmune inflammation, and Image Analysis Ltd, medical experts in imaging technology who will provide new innovative solutions based on analytics from MRI and new imaging biomarkers. The project will be performed in collaboration with Lund University BioImaging Center (LBIC) close to Redoxis facilities in Lund.The main objective of the project are implementation of Redoxis current and newly developed animal models of autoimmune diseases, including rheumatoid arthritis (RA) and multiple sclerosis (MS) with imaging technology from Image Analysis.

Peter Olofsson, CEO of Redoxis comments - "With the support from Eurostars, Redoxis will during the coming 2-3 years further develop and improve our preclinical models. The partnership with Image Analysis will also further strengthen our international market presence. The granted Eurostars funding is fundamental for Redoxis improved technical capacities and will enable us to continued growth and R&D capacity".

Redoxis AB, Medicon Village, Scheelevägen 2, SE- 221 84 Lund, Sweden.
Tel: +46 709 16 46 08, Mail: peter.olofsson@redoxis.com, http://www.redoxis.com

About Redoxis

Redoxis is an internationally leading CRO (Contract Research Organisation) with specialized focus and dedication on preclinical models of autoimmune disorders as tools to evaluate new treatments, for severe autoimmune disease like Multiple Sclerosis and Rheumatoid Arthritis. Redoxis provides reliable efficacy reports to facilitate decisions and funding for further development of candidate drugs towards clinical proof of concept studies. With a focused area of disease models, and an efficient and competent crew of researchers, we provide world-leading expertise and high value for our sponsors.

About Image Analysis

Image Analysis is a UK based company that support clinical and pre-clinical studies and provide earlier, convincing evidence for a therapeutic effect in inflammatory arthritis and inflammatory cancers by utilizing advanced imaging, computer-aided scoring routines and patented methodologies. Image Analysis delivers comprehensive services and innovative software algorithms for advanced medical imaging analytics. One of the most recognised tools from Image Analysis is the proprietary platform Dynamika provides automation, centralization and standardization for imaging-based clinical studies.

About Eurostars

The Eurostars is a European funding program specifically dedicated to stimulating translational innovation projects of small and medium enterprises that are developing innovative products, processes or services.

Redoxis AB, Medicon Village, Scheelevägen 2, SE- 221 84 Lund, Sweden.
Tel: +46 709 16 46 08, Mail: peter.olofsson@redoxis.com, http://www.redoxis.com